- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02734667
Initiation of Continuous Glucose Monitoring at Diagnosis of Type 1 Diabetes
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Synopsis of study protocol
This pilot randomized clinical trial compares newly diagnosed T1D youth who are started on CGM (the intervention group) versus those who are not (the control group). The investigators will examine group differences over a 6-month period (Phase 1) on two sets of outcomes: psychosocial variables and glycemic variables. After the initial comparison of intervention to control across the first six months after diagnosis, the investigators will conduct a longitudinal follow-up (Phase 2) of glycemic and psychosocial variables for an additional 18 months. The CGM system used in this study is the Dexcom G5 System with the Share function (FDA Approved). An IDE was obtained to use this system in a non-adjunctive manner. Participants will complete Phase 1 in six months. Phase 2 includes 3 more assessments conducted every six months until participants are two years post-diagnosis.
Study Procedures
Participants will be recruited at two centers: Stanford University and the Barbara Davis Center for Diabetes, University of Colorado. Participants will be enrolled while inpatient or within 1 month of diagnosis. Once identified, study staff will approach potential participants to explain the study, determine eligibility, and obtain informed consent. Once enrolled in the study, participants will be randomized. Participants will be randomized at a 2:1 ratio, intervention to control. The investigators will also stratify by age group to ensure equal representation of ages across groups. The age groups (in years) are 2-6, 7-11, and 12-17. To ensure safety in the youngest group, recruitment of participants in the age 2-6 years group will not begin until the investigators have at least 2 weeks of non-adjunctive CGM use data in at least 3 participants aged 7-17 years. Data will be reviewed by the DSMB on these 3 participants and if deemed safe by the DSMB, the investigators will start enrolling participants in the youngest age group.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford University
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
To be eligible for the study, a child must meet the following criteria:
- Diagnosis of type 1 diabetes according to American Diabetes Association diagnostic criteria
- Time since diagnosis of no longer than one month
- Age between 2 and 17 years
- Parental consent (and assent from the child where applicable) to participate in the study
- No severe medical conditions, which in the opinion of the investigators are likely to hinder participation in this clinical trial.
To be eligible for the study, a parent must meet the following criteria:
- Parent or legal guardian of a child with type 1 diabetes meeting the "child" criteria outlined above
- Age of 18.0 years or older
- Parent comprehends written English
- Parent understands the study protocol and signs the informed consent document
Exclusion Criteria:
The presence of any of the following is an exclusion for the study:
- Child has a medical disorder that in the judgment of the investigator will interfere with completion of any aspect of the protocol (e.g., pregnancy, kidney disease, adrenal insufficiency, skin condition that may hinder sensor application).
- Child has a neurologic disorder that in the judgment of the investigator will affect completion of the protocol
- Current use of oral glucocorticoids or other medications, which in the judgment of the investigator would be a contraindication to participation in the study
- Child is unable to completely avoid acetaminophen for duration of study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CGM at diagnosis of T1D
Participants start non-adjunctive use of CGM at diagnosis of T1D and continue for 6 months.
|
Initiation of non-adjunctive CGM use at diagnosis of T1D
|
No Intervention: Usual Care
Participants receive usual care for T1D for 6 months post diagnosis.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time Spent in Blood Glucose Range (70-180mg/dL)
Time Frame: Collected entire period for 6 months post-baseline; primary endpoint is 14 day period around that 6-month time point
|
Increasingly it is recognized that the percent time spent in a target blood glucose range, which is set by the American Diabetes Association, is an important outcome.
This measure will be used as a primary outcome and derived from objective data downloads.
It is calculated using the values for 14 days around the assessment time point.
|
Collected entire period for 6 months post-baseline; primary endpoint is 14 day period around that 6-month time point
|
Glucose Monitoring Satisfaction Survey (GMSS) - Parent
Time Frame: Baseline, 24 months
|
The GMSS is a validated survey created to measure the level of satisfaction a person with diabetes - type 1 or type 2 - experiences in response to monitoring glucose values.
It was validated in people using CGM.
Scores range 0 to 5 with higher scores indicating greater satisfaction.
|
Baseline, 24 months
|
Time Spent in Hypoglycemia (< 70 mg/dL)
Time Frame: Collected entire period for 6 months post-baseline; primary endpoint is 14 day period around that 6-month time point
|
Time spent in hypoglycemia is calculated using the values for 14 days around the assessment time point.
|
Collected entire period for 6 months post-baseline; primary endpoint is 14 day period around that 6-month time point
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pediatric Quality of Life Inventory
Time Frame: Baseline, 24 months
|
This is a measure of health-related quality of life.
It is used to understand the broader impact on quality of life which includes social, psychological, and health aspects of daily living.
Scores range from 0 to 100.
Higher scores indicate greater quality of life.
|
Baseline, 24 months
|
Problem Areas in Diabetes Score
Time Frame: Baseline, 24 months
|
Participants in the study report on daily problems with diabetes via this measure.
Respondents indicate the degree to which each of the items is currently a problem for them.
Score range: 0 to 4, higher scores correspond to more serious problems.
|
Baseline, 24 months
|
Diabetes Distress Scale
Time Frame: Baseline, 24 months
|
This measure is widely used to capture the psychological distress experienced in relation to diabetes.
Parent scale score range: 0-4.
Youth scale score range: 1-6.
Higher scores indicate greater diabetes-related distress.
|
Baseline, 24 months
|
Patient Health Questionnaire 9
Time Frame: Baseline, 24 months
|
This is a widely used measure that captures depressive symptoms, and was used to assess health symptoms in parents.
Score range: 0-24.
Higher scores indicate greater severity of symptoms.
|
Baseline, 24 months
|
State-Trait Anxiety Inventory
Time Frame: Baseline, 24 months
|
This is a widely used measure of anxiety symptoms, and was used to assess anxiety symptoms in parents.
Score range for both state-anxiety is: 20-80.
Higher scores indicate greater anxiety.
|
Baseline, 24 months
|
Pittsburgh Sleep Quality Index
Time Frame: Baseline, 24 months
|
This questionnaire measures the degree to which sleep is disrupted and the quality of sleep experienced by participants, and was used to assess sleep quality in parents.
Score range is: 0-21.
Higher scores indicate lower sleep quality.
|
Baseline, 24 months
|
Hypoglycemic Fear Survey
Time Frame: Baseline, 24 months
|
People with diabetes worry about hypoglycemia, and was used to assess parent's worry about their child.
This measure captures those worries.
Score range: 0-72.
Higher scores indicate greater fear and worry of hypoglycemia.
|
Baseline, 24 months
|
Hypoglycemic Confidence Questionnaire
Time Frame: Baseline, 24 months
|
Hypoglycemia needs to be managed in various daily situations.
This questionnaire captures confidence of the participants in those various situations, and was used to assess parent's confidence.
Score range: 8-32.
Higher scores indicate greater confidence to manage hypoglycemia.
|
Baseline, 24 months
|
General and Diabetes-specific Technology Use
Time Frame: Baseline, 24 months
|
This measure has questions on attitudes and use of various general technologies (e.g., smartphone) and diabetes devices.
Score range: 5-25.
Higher scores indicate more positive attitudes about technology.
|
Baseline, 24 months
|
Center for Epidemiologic Studies Depression Measure
Time Frame: Baseline, 24 months
|
This is a widely used measure of depression, and was used to assess depression symptoms in youths.
Score range: 0-60.
Higher scores indicate greater symptoms.
|
Baseline, 24 months
|
Child Health Utility 9D
Time Frame: Baseline, 24 months
|
Widely used measure of quality of life that is used to generate quality-adjusted life years, and was used to assess health symptoms in youth.
Each score scale is 0 to 4, with scores of 3 or 4 denoting more severe problems.
The count of participants responding 3 or higher for each parameter are presented.
|
Baseline, 24 months
|
Hemoglobin A1c
Time Frame: Baseline, 24 months
|
The hemoglobin A1c value is a biologic measure of the glycemia that is the gold standard measure of "control" of diabetes.
Collected through a blood sample.
|
Baseline, 24 months
|
C-peptide
Time Frame: Baseline, 24 months
|
This is a biologic measure of endogenous production and is collected through a blood sample.
|
Baseline, 24 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Korey K Hood, PhD, Stanford University
- Principal Investigator: Paul Wadwa, MD, University of Colorado, Denver
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 35990
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Spiden AGDCB Research AGRecruitingType 1 Diabetes Mellitus | Type 1 Diabetes Mellitus With Hypoglycemia | Type 1 Diabetes Mellitus With HyperglycemiaSwitzerland
-
Hoffmann-La RocheRoche DiagnosticsCompletedDiabetes Mellitus Type 2, Diabetes Mellitus Type 1Germany
Clinical Trials on CGM at diagnosis of T1D
-
Centre Hospitalier Universitaire, AmiensCompleted
-
National Taiwan University HospitalCompleted
-
Hospital General de MexicoUnknown
-
University Hospital, AngersNot yet recruitingPrimary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Myeloproliferative NeoplasmFrance
-
Azienda Ospedaliera Universitaria Integrata VeronaCompletedColorectal Cancer | Colorectal Carcinoma | Stage IV Colon CancerItaly
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, France; Centre National...UnknownDiabetes Mellitus | Insulin-DependentFrance
-
Children's Hospital of Eastern OntarioJuvenile Diabetes Research Foundation; Canadian Clinical Trial NetworkCompleted
-
IRCCS Burlo GarofoloRecruiting
-
First Affiliated Hospital Xi'an Jiaotong UniversityNot yet recruiting
-
Gruppo Italiano Malattie EMatologiche dell'AdultoCompleted